beurs_noob schreef op 5 jun 2019 om 22:41:
MY: See the totality of all of that is perhaps maybe underappreciated by the street
because it seems to just focused on one safety study in totality.
DOD: So, yes, I think with any medicine and any discussion with the regulator, you have to look at the benefit risk profile in totality. And I think in my experience that's the way, the FDA has always looked at medicines and products and so we need to have that discussion.
Mijn interpretatie: samenvoegen wordt door Daniel O'Day bevestigd inclusief te volgen van strategie van Gilead.
Rijst de vraag: zodra gesprekken met de FDA positief zijn afgerond wat dan? Knallen met het aandeel? Of overgenomen worden?